TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)

Tokino T and Nakamura Y: The role of p53-target genes in human cancer. Crit Rev Oncol Hematol. 33:1–6. 2000. View Article : Google Scholar : PubMed/NCBI

Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, et al: Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 23:e38–e45. 2017. View Article : Google Scholar : PubMed/NCBI

Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, Jones JL and Eccles DM: A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 47:771–774. 2010. View Article : Google Scholar : PubMed/NCBI

Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC and Arun BK: Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 118:908–913. 2012. View Article : Google Scholar : PubMed/NCBI

Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, et al: BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives 1. Eur J Cancer. 42:1143–1150. 2006. View Article : Google Scholar : PubMed/NCBI

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 12:1157–1167. 2006. View Article : Google Scholar : PubMed/NCBI

Varna M, Bousquet G, Plassa LF, Bertheau P and Janin A: TP53 status and response to treatment in breast cancers. J Biomed Biotechnol. 2011:2845842011. View Article : Google Scholar : PubMed/NCBI

Wang Y, Helland Å, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL and Kristiansen GB: TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer. 90:678–685. 2004. View Article : Google Scholar : PubMed/NCBI

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL and Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 9:R302007. View Article : Google Scholar : PubMed/NCBI

Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS and Jung SS: p53 as a specific prognostic factor in triple-negative breast cancer. Jap J Clin Oncol. 39:217–224. 2009. View Article : Google Scholar

Weisman PS, Ng CK, Brogi E, Eisenberg RE, Won HH, Piscuoglio S, De Filippo MR, Ioris R, Akram M, Norton L, et al: Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol. 29:476–488. 2016. View Article : Google Scholar : PubMed/NCBI

Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Ouesnel B, Deryite I, Morel P and Fenaux P: 53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:3148–3157. 1994.PubMed/NCBI

Børresen-Dale AL: TP53 and breast cancer. Hum Mutat. 21:292–300. 2003. View Article : Google Scholar : PubMed/NCBI

Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R and Ishioka C: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI

National Cancer Institute (NCI): NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms

Komarova EA, Chumakov PM and Gudcov AV: Molecular genetics of cancer. TP53 in cancer origin and treatment. Edited by Cowell JK. 9:195–221. 2009.

Hasty P and Christy BA: p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis. 3:227022013. View Article : Google Scholar

National Center for Biotechnology Information: The p53 tumor suppressor proteinGenes and Disease [Internet]. National Center for Biotechnology Information; Bethesda, MD, USA:

Sionov RV, Hayon IL and Haupt Y: The regulation of p53 growth suppression. Madame Curie Bioscience Database [Internet]Landes Bioscience. Austin, TX: 2000–2013

Shi D and Gu W: Dual roles of MDM2 in the regulation of p53. Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 3:240–248. 2012. View Article : Google Scholar : PubMed/NCBI

Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI

Hill KA and Sommer SS: p53 as a mutagen test in breast cancer. Environ Mol Mutagen. 39:216–227. 2002. View Article : Google Scholar : PubMed/NCBI

Pharoah PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer. 80:1968–1973. 1999. View Article : Google Scholar : PubMed/NCBI

Hainaut P and Hollstein M: p53 and human cancer: The first ten thousand mutations. Adv Cancer Res. 77:81–137. 2000. View Article : Google Scholar : PubMed/NCBI

Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1233–1238. 1990. View Article : Google Scholar : PubMed/NCBI

Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, et al: The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 245:96–102. 2007. View Article : Google Scholar : PubMed/NCBI

Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R and Fronza G: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene. 20:3573–3579. 2001. View Article : Google Scholar : PubMed/NCBI

Gasco M, Yulug IG and Crook T: TP53 mutations in familial breast cancer: Functional aspects. Hum Mutat. 21:301–306. 2003. View Article : Google Scholar : PubMed/NCBI

Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI

Li FP and Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med. 71:747–752. 1969. View Article : Google Scholar : PubMed/NCBI

Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA and Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res. 48:5358–5362. 1998.

Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP and Santibáñez-Koref MF: Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer. 70:1176–1181. 1994. View Article : Google Scholar : PubMed/NCBI

Brugières L, Gardes M, Moutou C, Chompret A, Meresse V, Matin A, Poisson N, Flamand F, Bonaïti-Pellié C, Lemerie J, et al: Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res. 53:452–455. 1993.PubMed/NCBI

Varley JM, Evans DG and Birch JM: Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer. 76:1–14. 1997. View Article : Google Scholar : PubMed/NCBI

Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J and Bonaïti-Pellié C: Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 38:43–47. 2001. View Article : Google Scholar : PubMed/NCBI

Hu H, Liu J, Liao X, Zhang S, Li H, Lu R, Li X, Lin W, Liu M, Xia Z, et al: Genetic and functional analysis of a Li Fraumeni syndrome family in China. Sci Rep. 6:202212016. View Article : Google Scholar : PubMed/NCBI

Olivier M, Hollstein M and Hainaut P: TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI

Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P and Eeles RA: Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 63:6643–6650. 2003.PubMed/NCBI

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI

Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G and Soussi T: The TP53 website: An integrative resource center for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 41:(Database Issue). D962–D969. 2013. View Article : Google Scholar : PubMed/NCBI

Assumpção JG, Seidinger AL, Mastellato MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, et al: Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer. 8:3572008. View Article : Google Scholar : PubMed/NCBI

Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P and Olivier M: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI

Brachmann RK, Vidal M and Boeke JD: Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA. 93:4091–4095. 1996. View Article : Google Scholar : PubMed/NCBI

Soussi T: The p53 tumor suppressor gene: From molecular biology to clinical investigation. Ann N Y Acad Sci. 910:121–139. 2000. View Article : Google Scholar : PubMed/NCBI

Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DAJ, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, et al: The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol. 22:86–96. 2004. View Article : Google Scholar : PubMed/NCBI

Overgaard J, Yilmaz M, Guldberg P, Hansen LL and Alsner J: TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 39:327–333. 2000. View Article : Google Scholar : PubMed/NCBI

Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar : PubMed/NCBI

Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B and Bergh J: Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol. 16:743–748. 2005. View Article : Google Scholar : PubMed/NCBI

Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB and Rose C: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol. 19:3376–3384. 2001. View Article : Google Scholar : PubMed/NCBI

Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson C, Barcos M, Hayes D and Norton L: HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 18:3471–3479. 2000. View Article : Google Scholar : PubMed/NCBI

Bergh J, Norberg T, Sjögren S, Lindgren A and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1:1029–1034. 1995. View Article : Google Scholar : PubMed/NCBI

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, et al: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 60:2155–2162. 2000.PubMed/NCBI

Powell BL, Bydder S, Grieu F, Gnanasampanthan G, Elsaleh H, Seshadri R, Berns EMJJ and Iacopetta B: Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Res Treat. 69:65–68. 2001. View Article : Google Scholar : PubMed/NCBI

Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandarad AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM and van den Vijver: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 16:470–479. 1998. View Article : Google Scholar : PubMed/NCBI

Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S and Theillet C: Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 60:1077–1083. 2000.PubMed/NCBI

Thorlacius S, Börresen AL and Eyfjörd JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res. 53:1637–1641. 1993.PubMed/NCBI

Bueno Martinez A, Molina MA, Fielding A, Bertran-Alamillo J, Dougherty BA, Lai Z, Hodgson D, de las Casas Mayo C, Rowe P, Gil M, et al: LBA42-Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO. 2017.

Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S and Trikalinos TA: Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: A systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol. 177:1317–1325. 2013. View Article : Google Scholar : PubMed/NCBI

Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A and Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered. 44:266–270. 1994. View Article : Google Scholar : PubMed/NCBI

Langerod A, Burdette L, Yeager M, Presswalla S, et al: Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press). 2006.

Pim D and Banks L: p53 Polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI

Siddique M and Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 25:3489–3500. 2006. View Article : Google Scholar : PubMed/NCBI

Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI

Harris SL, Gil G, Hu W, Robins H, Bond E, Hirshfield K, Feng Z, Yu X, Teresky AK, Bond G and Levine AJ: Single-nucleotide polymorphisms in the p53 pathway. Cold Spring Harb Symp Quant Biol. 70:111–119. 2005. View Article : Google Scholar : PubMed/NCBI

Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H and Fujii Y: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9:R342007. View Article : Google Scholar : PubMed/NCBI

Paulin FE, O'Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, Munro AJ, Baker L, Purdie CA, Lane DP and Thompson AM: MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer. 8:2812008. View Article : Google Scholar : PubMed/NCBI

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version I. simpleNCCN.orgFort Washington, DC: 2015

Hu Z, Li X, Qu X, He Y, Ring BZ, Song E and Su L: Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: A meta-analysis. Carcinogenesis. 31:643–647. 2010. View Article : Google Scholar : PubMed/NCBI

Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, et al: DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat. 31:456–465. 2010. View Article : Google Scholar : PubMed/NCBI

Li X, Dumont P, Della Pietra A, Shetler C and Murphy ME: The codon 47 polymorphism in p53 is functionally significant. J Biol Chem. 280:24245–24251. 2005. View Article : Google Scholar : PubMed/NCBI

National Institute for Health and Care Excellence (NICE): Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerClinical guideline [CG164]. NICE; London: 2013, https://www.nice.org.uk/guidance/cg164June. 2013

The Institute of Cancer Research (ICR): Division of Genetics and EpidemiologyICR; London: https://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-epidemiologyCancer Genetic Clinical Protocols.